AIKIDO PHARMA INC (AIKI) Fundamental Analysis & Valuation

NASDAQ:AIKI • US0088753043

Current stock price

3.56 USD
+0.01 (+0.28%)
Last:

This AIKI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. AIKI Profitability Analysis

1.1 Basic Checks

  • AIKI had negative earnings in the past year.
  • AIKI had a negative operating cash flow in the past year.
AIKI Yearly Net Income VS EBIT VS OCF VS FCFAIKI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -5M -10M

1.2 Ratios

  • The profitability ratios for AIKI are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AIKI Yearly ROA, ROE, ROICAIKI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AIKI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIKI Yearly Profit, Operating, Gross MarginsAIKI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -20K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. AIKI Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for AIKI has been reduced compared to 1 year ago.
  • AIKI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AIKI Yearly Shares OutstandingAIKI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
AIKI Yearly Total Debt VS Total AssetsAIKI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of 1.78, we must say that AIKI is in the distress zone and has some risk of bankruptcy.
  • With a decent Altman-Z score value of 1.78, AIKI is doing good in the industry, outperforming 65.88% of the companies in the same industry.
  • AIKI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.78
ROIC/WACCN/A
WACCN/A
AIKI Yearly LT Debt VS Equity VS FCFAIKI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 29.54 indicates that AIKI has no problem at all paying its short term obligations.
  • AIKI's Current ratio of 29.54 is amongst the best of the industry. AIKI outperforms 96.24% of its industry peers.
  • AIKI has a Quick Ratio of 29.54. This indicates that AIKI is financially healthy and has no problem in meeting its short term obligations.
  • AIKI has a Quick ratio of 29.54. This is amongst the best in the industry. AIKI outperforms 96.24% of its industry peers.
Industry RankSector Rank
Current Ratio 29.54
Quick Ratio 29.54
AIKI Yearly Current Assets VS Current LiabilitesAIKI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AIKI Growth Analysis

3.1 Past

  • AIKI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -879.05%.
EPS 1Y (TTM)-879.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12993.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • AIKI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.65% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-245.59%
EPS Next 2Y-5.02%
EPS Next 3Y23.38%
EPS Next 5Y11.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AIKI Yearly Revenue VS EstimatesAIKI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2024 2025 2026 5M 10M 15M 20M
AIKI Yearly EPS VS EstimatesAIKI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. AIKI Valuation Analysis

4.1 Price/Earnings Ratio

  • AIKI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AIKI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIKI Price Earnings VS Forward Price EarningsAIKI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIKI Per share dataAIKI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • AIKI's earnings are expected to grow with 23.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.02%
EPS Next 3Y23.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AIKI Dividend Analysis

5.1 Amount

  • No dividends for AIKI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AIKI Fundamentals: All Metrics, Ratios and Statistics

AIKIDO PHARMA INC

NASDAQ:AIKI (12/21/2022, 8:17:10 PM)

3.56

+0.01 (+0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.14%
Ins Owner Change0%
Market Cap19.53M
Revenue(TTM)N/A
Net Income(TTM)-16.66M
Analysts82.86
Price Target16.32 (358.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-59.55%
Min EPS beat(2)-70.13%
Max EPS beat(2)-48.97%
EPS beat(4)0
Avg EPS beat(4)-77.81%
Min EPS beat(4)-96.08%
Max EPS beat(4)-48.97%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-55.56%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-17.5%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-3.37
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-2.07
FCFYN/A
OCF(TTM)-1.97
OCFYN/A
SpS0
BVpS14.92
TBVpS15.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 29.54
Quick Ratio 29.54
Altman-Z 1.78
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-879.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12993.62%
EPS Next Y-245.59%
EPS Next 2Y-5.02%
EPS Next 3Y23.38%
EPS Next 5Y11.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-67.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.75%
OCF growth 3YN/A
OCF growth 5YN/A

AIKIDO PHARMA INC / AIKI Fundamental Analysis FAQ

What is the fundamental rating for AIKI stock?

ChartMill assigns a fundamental rating of 3 / 10 to AIKI.


Can you provide the valuation status for AIKIDO PHARMA INC?

ChartMill assigns a valuation rating of 3 / 10 to AIKIDO PHARMA INC (AIKI). This can be considered as Overvalued.


What is the profitability of AIKI stock?

AIKIDO PHARMA INC (AIKI) has a profitability rating of 1 / 10.


What is the earnings growth outlook for AIKIDO PHARMA INC?

The Earnings per Share (EPS) of AIKIDO PHARMA INC (AIKI) is expected to decline by -245.59% in the next year.